Skip to content

Study · Systematic review · n = 94 · 2023

3 results

The efficacy of intranasal oxytocin in patients with Prader-Willi syndrome: A systematic review and meta-analysis.

Shalma NM, Alsharabasy MA, Taha AM, Alsawareah A, Manirambona E, Ahmed SK, Mohamed MR, Taha NA, Abd-ElGawad M

Diabetes & metabolic syndrome4 Feb 2023Cited by 9 (Europe PMC)

PMID36774885 (opens in a new tab)DOI10.1016/j.dsx.2023.102711 (opens in a new tab)PepBankPUB-36774885
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In patients with Prader-Willi syndrome, pooled data from three studies showed no significant effect of oxytocin on weight versus placebo.

    In plain wordsIn people with Prader-Willi syndrome, pooled trials showed oxytocin did not change weight compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeBody weight
    Study

    n = 94

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Mean difference
    0.3 NA
    weight

    Source sentences

    Summary
    Three studies that included 94 patients revealed no significant effects regarding weight between oxytocin and placebo (MD = 0.30; 95% CI: -0.22, 0.83; P = 0.25).
    1 context sentence
    Summary · context
    We conducted a systematic literature search on Pubmed, Web of Science, and Scopus from inception to March 2022 for relevant interventional randomized controlled trials (RCTs) reporting the effect of oxytocin in patients with Prader-Willi syndrome.
  2. 02HumanSystematic reviewEfficacy outcome

    In patients with Prader-Willi syndrome, pooled data from three studies showed no benefit of oxytocin over placebo on hyperphagia.

    In plain wordsIn people with Prader-Willi syndrome, pooled trials showed oxytocin did not reduce overeating compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeHyperphagia
    Study

    n = 92

    Comparator
    Placebo
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Measurements

    Mean difference
    0.18 NA
    hyperphagia

    Source sentences

    Summary
    Relevant to hyperphagia, the data extracted in three studies comprising 92 patients did not show positive outcomes of oxytocin compared to placebo (MD = 0.18; 95% CI: -0.44, 0.80; P = 0.56).
    1 context sentence
    Summary · context
    We conducted a systematic literature search on Pubmed, Web of Science, and Scopus from inception to March 2022 for relevant interventional randomized controlled trials (RCTs) reporting the effect of oxytocin in patients with Prader-Willi syndrome.
  3. 03HumanSystematic reviewEfficacy outcome

    In patients with Prader-Willi syndrome, the Aberrant Behaviour Checklist showed improved behaviour with oxytocin compared with placebo.

    In plain wordsIn people with Prader-Willi syndrome, behaviour scores improved with oxytocin compared with placebo.

    Peptide
    Oxytocin
    Outcome
    Direction not reportedAberrant Behaviour Checklist
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Psychiatric symptoms · Mental health and mood
    Studied dose
    Dose not stated · intranasalAs given in this study (human).

    Source sentences

    Summary
    The Aberrant Behaviour Checklist found that group-administered oxytocin improved behaviour compared to their counterpart who received a placebo.
    1 context sentence
    Summary · context
    We conducted a systematic literature search on Pubmed, Web of Science, and Scopus from inception to March 2022 for relevant interventional randomized controlled trials (RCTs) reporting the effect of oxytocin in patients with Prader-Willi syndrome.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.